Global Dengue Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product Type;
ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test and Other Tests.By End User;
Hospitals, Diagnostic Centers and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Dengue Testing Market (USD Million), 2021 - 2031
In the year 2024, the Global Dengue Testing Market was valued at USD 552.31 million. The size of this market is expected to increase to USD 765.06 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.8%.
The COVID-19 pandemic exerted a significant impact on the dengue testing market, with both viruses sharing similar early-stage symptoms. This led to a substantial portion of the population undergoing dengue testing, thereby driving market growth. For instance, reports from June of the base year highlighted cases in Singapore where individuals initially diagnosed with dengue fever later tested positive for COVID-19, underscoring the need for accurate testing amidst the pandemic. Additionally, various regions worldwide witnessed a surge in dengue cases during the pandemic, necessitating increased testing demand.
Factors contributing to market growth include the rising incidence of dengue cases and heightened awareness campaigns. The global incidence of dengue has seen a significant uptick in recent years, with millions of cases reported annually across countries like Brazil, Peru, Vietnam, Indonesia, and Colombia. Government and healthcare initiatives to curb dengue transmission, as seen in campaigns launched by organizations like DoH-CHD in the Philippines, further bolster market growth. Moreover, strategic business moves such as acquisitions, partnerships, and product launches, such as the approval of SARAGENE Dengue Test Kit by CDSCO and Roche's acquisition of GenMark, indicate a growing focus on expanding dengue testing capabilities.
Nevertheless, challenges such as the lack of effective diagnostic tools and high test kit prices may impede market growth. Overcoming these hurdles will be crucial for sustaining market expansion over the forecast period, ensuring timely and accurate diagnosis of dengue cases to mitigate its impact on public health.
Global Dengue Testing Market Recent Developments
-
In September 2024, QIAGEN unveiled the broadening of its strategic partnership with Bio,Manguinhos/Fiocruz, the principal provider of vaccines and diagnostics for the Brazilian Ministry of Health. The expanded partnership now allows Bio,Manguinhos to introduce a sophisticated PCR,based molecular screening platform capable of detecting malaria in addition to HIV, and hepatitis B and C (HBV and HCV). This extension also enhances epidemiological monitoring of Brazil's prevalent dengue fever by implementing dengue molecular kits designed with exclusive chemistry developed jointly by QIAGEN and Bio,Manguinhos/Fiocruz. QIAGEN is set to deliver vital molecular biology technologies, tailored solutions, and extensive training to support Brazil’s public health efforts.
-
In August 2024, J Mitra & Company introduced the Dengue NS1 Antigen self,test kit, the first of its kind for home use in India. This kit enables individuals to perform the test autonomously at any chosen location and delivers results in 20 minutes through a rapid visual test, simplifying result interpretation. The kit effectively detects all four serotypes of the Dengue virus, known for its high sensitivity and accuracy. It falls under the category of Point of Care Test (POCT) and is designed for ease of use without the need for specialized training. The testing process involves placing a drop of blood into the sample well, adding a drop of assay buffer, and obtaining results within 20 minutes.
Segment Analysis
The global dengue testing market is experiencing significant growth, driven by the increasing demand for various testing methods to diagnose dengue infections accurately. ELISA-based tests, RT-PCR based tests, Dengue IgG/IgM rapid tests, and other innovative testing approaches are key contributors to this market expansion. ELISA-based tests offer high sensitivity and specificity in detecting dengue virus antigens or antibodies, making them widely used in clinical laboratories and healthcare settings for dengue diagnosis.
Similarly, RT-PCR based tests provide precise detection of dengue virus RNA, enabling early and accurate diagnosis of dengue infections. These tests are particularly valuable in detecting viral RNA during the acute phase of infection, facilitating timely medical intervention. Dengue IgG/IgM rapid tests offer rapid results within minutes and are suitable for point-of-care testing, enhancing accessibility and convenience for patients. Additionally, ongoing advancements in diagnostic technologies are driving the development of other innovative tests, further expanding the options available for dengue testing. As the global burden of dengue continues to rise, fueled by factors such as urbanization, travel, and climate change, the demand for diverse and effective testing methods is expected to fuel the growth of the dengue testing market.
Global Dengue Testing Segment Analysis
In this report, the Global Dengue Testing Market has been segmented by Product Type, End User and Geography.
Product Type segmentation includes various testing methods such as ELISA-based tests, RT-PCR based tests, Dengue IgG/IgM rapid tests, and other innovative testing approaches. These diverse testing methods cater to different diagnostic needs and preferences, offering healthcare providers a range of options for accurate dengue diagnosis.
Furthermore, End User segmentation encompasses various healthcare settings and facilities where dengue testing is performed, including hospitals, clinics, diagnostic laboratories, and research institutions. Understanding the preferences and requirements of different end users is essential for effectively meeting the demand for dengue testing solutions across diverse healthcare settings. Geographical segmentation covers key regions such as North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, providing insights into regional market dynamics, growth opportunities, and regulatory landscapes. This comprehensive segmentation approach enables stakeholders to identify growth opportunities, formulate strategic decisions, and stay competitive in the dynamic global dengue testing market landscape.
Global Dengue Testing Market, Segmentation by Product Type
The Global Dengue Testing Market has been segmented by Product Type into ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test and Other Tests.
ELISA-based tests offer high sensitivity and specificity, making them suitable for laboratory settings where accurate diagnosis is paramount. RT-PCR based tests are valued for their ability to detect viral RNA and provide rapid results, making them indispensable tools for early diagnosis and outbreak management.
Moreover, Dengue IgG/IgM Rapid Tests offer the advantage of quick turnaround time and ease of use, making them suitable for point-of-care settings and resource-limited environments. Other innovative testing methods cater to specific diagnostic needs and technological advancements in dengue testing, driving continuous innovation and expansion in the market. This segmentation facilitates a nuanced understanding of the market landscape, allowing stakeholders to identify key growth opportunities, address unmet needs, and develop targeted strategies to navigate the competitive market environment effectively.
Global Dengue Testing Market, Segmentation by End User
The Global Dengue Testing Market has been segmented by End User into Hospitals, Diagnostic Centers and Others.
Hospitals serve as primary hubs for patient care, diagnosis, and treatment, making them significant end users of dengue testing services. With the high prevalence of dengue fever cases presenting at hospitals, the demand for accurate and timely diagnostic testing is substantial.
Diagnostic centers play a crucial role in dengue testing by providing specialized laboratory services, including ELISA-based tests, RT-PCR tests, and rapid diagnostic tests, to confirm dengue virus infection. These centers offer comprehensive diagnostic solutions, catering to the needs of healthcare providers, public health agencies, and individuals seeking timely and reliable testing for dengue fever. Additionally, other end users, such as clinics, urgent care centers, and research laboratories, contribute to the demand for dengue testing services, further expanding the market's reach and impact. This segmentation enables a focused analysis of the market dynamics and facilitates targeted marketing strategies to meet the diverse needs of end users across different healthcare settings.
Global Dengue Testing Market, Segmentation by Geography
In this report, the Global Dengue Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Dengue Testing Market Share (%), by Geographical Region, 2024
North America and Europe, although not endemic for dengue fever, play a crucial role in the market due to their advanced healthcare infrastructure and research activities. These regions often serve as key contributors to the development and validation of new dengue testing technologies.
Asia Pacific, on the other hand, is a region with a high burden of dengue fever, making it a significant market for dengue testing. The densely populated countries in this region, coupled with favorable climatic conditions for the Aedes mosquito vector, contribute to the high prevalence of dengue fever. As a result, there is a growing demand for dengue testing solutions in Asia Pacific, driving market growth. Similarly, the Middle East and Africa, as well as Latin America, are regions where dengue fever is endemic, leading to a continuous need for effective and accurate dengue testing methods. Understanding the market dynamics across these regions is essential for stakeholders to develop targeted strategies and address the specific challenges and opportunities present in each geographical segment.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Dengue Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers :
- Rising burden of dengue fever
- Increasing government initiatives
-
Technological advancements- Technological advancements play a pivotal role in shaping the landscape of the global dengue testing market. Over the years, significant progress has been made in the development of diagnostic tools and techniques, leading to more accurate, sensitive, and efficient testing methods for dengue fever. One notable advancement is the development of rapid diagnostic tests (RDTs) based on immunochromatographic assays, which allow for quick and point-of-care testing without the need for specialized laboratory equipment. These RDTs enable healthcare providers to obtain rapid results, facilitating timely diagnosis and patient management.
Furthermore, advancements in molecular diagnostics, such as real-time polymerase chain reaction (RT-PCR) and nucleic acid amplification tests (NAATs), have revolutionized dengue testing by offering high sensitivity and specificity in detecting the dengue virus's genetic material. These molecular techniques not only aid in early diagnosis but also enable the differentiation of dengue virus serotypes, which is crucial for epidemiological surveillance and outbreak management. Moreover, continuous research and innovation in the field of serological assays, including enzyme-linked immunosorbent assays (ELISAs) and IgG/IgM antibody tests, have led to the development of more sensitive and specific diagnostic platforms, enhancing the accuracy of dengue diagnosis.
Restraints :
- High cost of tests
-
Lack of skilled personnel - The Global Dengue Testing Market faces challenges related to the lack of skilled personnel, particularly in regions with high dengue prevalence. Performing accurate dengue testing requires trained laboratory technicians who can handle various testing methods and interpret results effectively. However, in many parts of the world, especially in resource-constrained settings, there is a shortage of skilled healthcare professionals trained in dengue diagnostics.
This shortage of skilled personnel poses several challenges for the effective management of dengue fever. Without adequately trained technicians, healthcare facilities may struggle to perform timely and accurate testing, leading to delays in diagnosis and treatment. Moreover, the misinterpretation of test results due to insufficient training can result in incorrect diagnoses, potentially compromising patient care and public health efforts to control dengue outbreaks. Addressing this challenge requires investments in training programs and capacity building initiatives to ensure that healthcare workers have the necessary skills and knowledge to perform dengue testing accurately and efficiently. Additionally, leveraging technology and automation in testing procedures can help mitigate the impact of the shortage of skilled personnel by streamlining processes and reducing the reliance on manual labor. By addressing the issue of the lack of skilled personnel, stakeholders can enhance the quality of dengue testing services and improve patient outcomes in regions affected by the disease.
Opportunity :
- Development of low-cost tests
- Rising focus on point-of-care testing
-
Growing emphasis on automation - The Global Dengue Testing Market is witnessing a growing emphasis on automation, driven by the need for increased efficiency, accuracy, and scalability in dengue testing processes. Automation in dengue testing involves the use of advanced laboratory instrumentation and robotic systems to perform various testing steps, including sample preparation, analysis, and result interpretation. This automation not only streamlines the testing workflow but also reduces the risk of human error, thereby improving the reliability of test results.
Moreover, automation enables laboratories to handle larger volumes of samples efficiently, making it particularly beneficial in regions with high dengue prevalence. By automating repetitive tasks and standardizing testing procedures, laboratories can enhance productivity and throughput while ensuring consistent quality and adherence to regulatory standards. As a result, there is a growing adoption of automated dengue testing solutions by hospitals, diagnostic centers, and other end users worldwide, driving the growth of the global dengue testing market.
Competitive Landscape Analysis
Key players in Global Dengue Testing Market include
- Thermo Fisher Scientific Inc
- Roche Molecular Systems Inc
- Abbott Laboratories
- InBios International
- NovaTec Immundiagnostica GmbH
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Dengue Testing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising burden of dengue fever
- Increasing government initiatives
- Technological advancements
- Restraints
- High cost of tests
- Lack of skilled personnel
- Opportunities
- Development of low-cost tests
- Rising focus on point-of-care testing
- Growing emphasis on automation
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Dengue Testing Market, By Product Type, 2021 - 2031 (USD Million)
- ELISA-based Tests
- RT-PCR based Tests
- Dengue IgG/IgM Rapid Test
- Other Tests
- Global Dengue Testing Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Diagnostic Centers
- Others
- Global Dengue Testing Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Dengue Testing Market, By Product Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific Inc
- Roche Molecular Systems Inc
- Abbott Laboratories
- InBios International, Inc
- NovaTec Immundiagnostica GmbH
- Company Profiles
- Analyst Views
- Future Outlook of the Market